Literature DB >> 418345

Neuropathology of tissues from patients treated by the Brain Tumor Study Group.

M S Mahaley, F S Vogel, P Burger, N R Ghatak.   

Abstract

The histopathologic diagnoses in 718 brain tumor patients entered in the Brain Tumor Study Group were reviewed, as well as those for 53 of these patients who were reviewed, as well as those for 53 of these patients who were autopsied later. This review documented instances of progression of histologic analplasia. Of particular interest in the autopsied cases were several instances of extensive necrosis in white matter distant from persisting glioma following chemotherapy and radiotherapy. This observation suggested the presence of a structural and/or metabolic alteration in the diseased hemisphere that perhaps makes it more susceptible to further alterations secondary to the adjunctive therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 418345

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  4 in total

Review 1.  Glial ontogeny and glial neoplasia: the search for closure.

Authors:  M E Linskey
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

2.  Pathology of human malignant gliomas after radiation and chemotherapy.

Authors:  D Schiffer; M T Giordana; P Paoletti; R Soffietti; L Tarenzi
Journal:  Acta Neurochir (Wien)       Date:  1980       Impact factor: 2.216

3.  Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis.

Authors:  L R Rogers; J Gutierrez; L Scarpace; L Schultz; S Ryu; B Lord; B Movsas; J Honsowetz; R Jain
Journal:  J Neurooncol       Date:  2010-05-20       Impact factor: 4.130

4.  Comparison of radiological and clinical features of temporal lobe necrosis in nasopharyngeal carcinoma patients treated with 2D radiotherapy or intensity-modulated radiotherapy.

Authors:  Y-P Mao; G-Q Zhou; L-Z Liu; R Guo; Y Sun; L Li; A-H Lin; M-S Zeng; T-B Kang; W-H Jia; J-Y Shao; H-Q Mai; J Ma
Journal:  Br J Cancer       Date:  2014-05-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.